Clinical Trials | December 09, 2025
Pharvaris’ deucrictibant shows rapid relief for hereditary angioedema in pivotal Phase 3 trial
The study met its primary endpoint and all 11 secondary efficacy endpoints
The study met its primary endpoint and all 11 secondary efficacy endpoints
Subscribe To Our Newsletter & Stay Updated